Dataset Preview
Duplicate
The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
The dataset generation failed
Error code:   DatasetGenerationError
Exception:    ArrowInvalid
Message:      JSON parse error: Column() changed from object to string in row 0
Traceback:    Traceback (most recent call last):
                File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/packaged_modules/json/json.py", line 174, in _generate_tables
                  df = pandas_read_json(f)
                File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/packaged_modules/json/json.py", line 38, in pandas_read_json
                  return pd.read_json(path_or_buf, **kwargs)
                File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/io/json/_json.py", line 815, in read_json
                  return json_reader.read()
                File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/io/json/_json.py", line 1025, in read
                  obj = self._get_object_parser(self.data)
                File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/io/json/_json.py", line 1051, in _get_object_parser
                  obj = FrameParser(json, **kwargs).parse()
                File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/io/json/_json.py", line 1187, in parse
                  self._parse()
                File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/io/json/_json.py", line 1402, in _parse
                  self.obj = DataFrame(
                File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/core/frame.py", line 778, in __init__
                  mgr = dict_to_mgr(data, index, columns, dtype=dtype, copy=copy, typ=manager)
                File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/core/internals/construction.py", line 503, in dict_to_mgr
                  return arrays_to_mgr(arrays, columns, index, dtype=dtype, typ=typ, consolidate=copy)
                File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/core/internals/construction.py", line 114, in arrays_to_mgr
                  index = _extract_index(arrays)
                File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/core/internals/construction.py", line 677, in _extract_index
                  raise ValueError("All arrays must be of the same length")
              ValueError: All arrays must be of the same length
              
              During handling of the above exception, another exception occurred:
              
              Traceback (most recent call last):
                File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1815, in _prepare_split_single
                  for _, table in generator:
                File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 692, in wrapped
                  for item in generator(*args, **kwargs):
                File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/packaged_modules/json/json.py", line 177, in _generate_tables
                  raise e
                File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/packaged_modules/json/json.py", line 151, in _generate_tables
                  pa_table = paj.read_json(
                File "pyarrow/_json.pyx", line 308, in pyarrow._json.read_json
                File "pyarrow/error.pxi", line 154, in pyarrow.lib.pyarrow_internal_check_status
                File "pyarrow/error.pxi", line 91, in pyarrow.lib.check_status
              pyarrow.lib.ArrowInvalid: JSON parse error: Column() changed from object to string in row 0
              
              The above exception was the direct cause of the following exception:
              
              Traceback (most recent call last):
                File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1451, in compute_config_parquet_and_info_response
                  parquet_operations, partial, estimated_dataset_info = stream_convert_to_parquet(
                File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 994, in stream_convert_to_parquet
                  builder._prepare_split(
                File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1702, in _prepare_split
                  for job_id, done, content in self._prepare_split_single(
                File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1858, in _prepare_split_single
                  raise DatasetGenerationError("An error occurred while generating the dataset") from e
              datasets.exceptions.DatasetGenerationError: An error occurred while generating the dataset

Need help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.

id
string
ID
string
context
string
task_type
string
question
string
options
list
answer
string
0
04276-Interventions-001
pmc.ncbi_PMC5290054
Interventions
What type of intervention was used in the treatment group?
[ "A. Lactobacillus casei strain Shirota fermented milk", "B. Yogurt", "C. Regular milk", "D. Probiotic capsules" ]
A
1
04276-Interventions-002
pmc.ncbi_PMC5290054
Interventions
What was the main characteristic of the control group in the study?
[ "A. Probiotic fermented milk", "B. Control milk", "C. Lactobacillus casei strain Shirota", "D. Fermented yogurt" ]
B
2
04276-Methods-001
pmc.ncbi_PMC5290054
Methods
What type of study design was used in this research?
[ "A. Cohort study", "B. Randomised controlled trial", "C. Case-control study", "D. Cross-sectional study" ]
B
3
04276-Methods-002
pmc.ncbi_PMC5290054
Methods
What was the duration of the study?
[ "A. 8 weeks", "B. 12 weeks", "C. 16 weeks", "D. 6 weeks" ]
B
4
04276-Methods-003
pmc.ncbi_PMC5290054
Methods
How many participants were excluded postrandomisation?
[ "A. 1", "B. 2", "C. 3", "D. 4" ]
C
5
04276-Methods-004
pmc.ncbi_PMC5290054
Methods
How many participants were lost to follow‐up during the study?
[ "A. 0", "B. 1", "C. 2", "D. 3" ]
A
6
04276-Methods-005
pmc.ncbi_PMC5290054
Methods
In the study, how many participants were excluded from the probiotic bacteria group?
[ "A. 0", "B. 1", "C. 2", "D. 3" ]
B
7
04276-Participants-001
pmc.ncbi_PMC5290054
Participants
What is the total number of participants in the RCT study?
[ "A. 80", "B. 90", "C. 100", "D. 110" ]
C
8
04276-Participants-002
pmc.ncbi_PMC5290054
Participants
How many participants were in the probiotic bacteria group?
[ "A. 30", "B. 50", "C. 70", "D. 100" ]
B
9
04276-Participants-003
pmc.ncbi_PMC5290054
Participants
In what age range were the participants of the study?
[ "A. 20 to 29 years", "B. 30 to 49 years", "C. 50 to 69 years", "D. 70 to 89 years" ]
B
10
04276-Participants-004
pmc.ncbi_PMC5290054
Participants
Which country did the participants of the RCT study reside in?
[ "A. South Korea", "B. Japan", "C. China", "D. Taiwan" ]
B
11
04276-Participants-005
pmc.ncbi_PMC5290054
Participants
What type of workplace setting were participants recruited from?
[ "A. Factories", "B. Retail stores", "C. Office buildings", "D. Remote locations" ]
C
12
04276-Participants-006
pmc.ncbi_PMC5290054
Participants
Which of the following was an exclusion criterion for participants in the study?
[ "A. Being a healthy male worker", "B. Living in Tokyo or its suburbs", "C. Having a history of influenza vaccination in the last 6 months", "D. Being between 30 to 49 years old" ]
C
13
04276-Participants-007
pmc.ncbi_PMC5290054
Participants
How many participants were in the placebo group?
[ "A. 20", "B. 30", "C. 50", "D. 60" ]
C
14
04276-Participants-008
pmc.ncbi_PMC5290054
Participants
Which of the following health conditions would exclude a participant from the study?
[ "A. Headaches", "B. Pollinosis", "C. Fatigue", "D. Mild allergies" ]
B
15
04276-Participants-009
pmc.ncbi_PMC5290054
Participants
What was one requirement for participants regarding their location of work?
[ "A. Must work in a home office", "B. Must work in a factory", "C. Must work inside an office building", "D. Must work remotely" ]
C
16
04276-Participants-010
pmc.ncbi_PMC5290054
Participants
How often could participants work outside the office building to remain eligible for the study?
[ "A. Once a week", "B. Twice a week or more", "C. Not at all", "D. Three times a week" ]
B
17
04276-Outcomes-001
pmc.ncbi_PMC5290054
Outcomes
What is the primary outcome measured in the RCT study?
[ "A. NK cell activity", "B. Level of immunoglobulin A (IgA) in saliva", "C. Incidence of URTIs", "D. Overall health improvement" ]
C
18
04276-Outcomes-002
pmc.ncbi_PMC5290054
Outcomes
Which of the following is a secondary endpoint in the RCT study?
[ "A. Incidence of URTIs", "B. Quality of life assessment", "C. NK cell activity", "D. Mortality rates" ]
C
19
04276-Outcomes-003
pmc.ncbi_PMC5290054
Outcomes
In the context of the study, which substance's level is being measured in saliva as a secondary endpoint?
[ "A. Cytokines", "B. Immunoglobulin A (IgA)", "C. Immunoglobulin M (IgM)", "D. T helper cells" ]
B
20
06891-Patient Sampling-001
pmc.ncbi_PMC3914762
Patient Sampling
What percentage of the patients in cohort 2 were male?
[ "A. 50%", "B. 76%", "C. 64%", "D. 82%" ]
B
21
06891-Patient Sampling-002
pmc.ncbi_PMC3914762
Patient Sampling
How many healthy controls were included in cohort 2?
[ "A. 50", "B. 25", "C. 91", "D. 23" ]
B
22
15638-Methods-001
pmc.ncbi_PMC2898909
Methods
What type of study design was used in this RCT?
[ "A. Cohort study", "B. Cross-sectional study", "C. Randomized Controlled Trial (RCT)", "D. Case-control study" ]
C
23
15638-Methods-002
pmc.ncbi_PMC2898909
Methods
What was the follow-up duration after randomization?
[ "A. 1 month", "B. 6 months", "C. 3 months", "D. 1 year" ]
A
24
15638-Methods-003
pmc.ncbi_PMC2898909
Methods
What was the attrition rate observed in the study?
[ "A. 10%", "B. 19%", "C. 25%", "D. 5%" ]
B
25
15638-Methods-004
pmc.ncbi_PMC2898909
Methods
Did the attrition rates significantly differ across study conditions?
[ "A. Yes they differed significantly", "B. No they did not differ significantly", "C. They were not recorded", "D. Yes they were equal" ]
B
26
15638-Methods-005
pmc.ncbi_PMC2898909
Methods
Was an intention-to-treat (ITT) analysis performed?
[ "A. Yes", "B. No", "C. Only for some groups", "D. Information not provided" ]
B
27
15638-Methods-006
pmc.ncbi_PMC2898909
Methods
At what level was randomization conducted in this study?
[ "A. Community level", "B. Group level", "C. Individual level", "D. Family level" ]
C
28
15638-Methods-007
pmc.ncbi_PMC2898909
Methods
Was the clustering effect adjusted in this study?
[ "A. Yes", "B. No", "C. Only partially", "D. Cannot be determined" ]
B
29
15638-Participants-001
pmc.ncbi_PMC2898909
Participants
What was the total number of participants that were randomly assigned in the RCT study?
[ "A. 375", "B. 385", "C. 335", "D. 113" ]
B
30
15638-Participants-002
pmc.ncbi_PMC2898909
Participants
How many participants actually participated in the RCT study?
[ "A. 375", "B. 113", "C. 385", "D. 335" ]
A
31
15638-Participants-003
pmc.ncbi_PMC2898909
Participants
How many participants were included in the analyzed sample of the study?
[ "A. 375", "B. 113", "C. 335", "D. 385" ]
C
32
15638-Participants-004
pmc.ncbi_PMC2898909
Participants
What was the average age of participants in the study?
[ "A. 15 years", "B. 16 years", "C. 17 years", "D. 18 years" ]
C
33
15638-Participants-005
pmc.ncbi_PMC2898909
Participants
What percentage of participants in the study identified as male?
[ "A. 30%", "B. 43%", "C. 53%", "D. 60%" ]
B
34
15638-Participants-006
pmc.ncbi_PMC2898909
Participants
Which ethnic group had the highest representation among the participants?
[ "A. Hispanic", "B. Black", "C. White", "D. Asian" ]
C
35
15638-Participants-007
pmc.ncbi_PMC2898909
Participants
What percentage of participants reported alcohol use over the past 30 days?
[ "A. 30%", "B. 40%", "C. 44%", "D. 50%" ]
C
36
15638-Participants-008
pmc.ncbi_PMC2898909
Participants
In which country was the RCT study conducted?
[ "A. Canada", "B. Australia", "C. United Kingdom", "D. United States" ]
D
37
15638-Interventions-001
pmc.ncbi_PMC2898909
Interventions
What is the primary focus of Intervention-1: Goal Survey?
[ "A. To help students develop contracts for goal setting", "B. To influence multiple health habits by addressing images of college and career success", "C. To provide consultative feedback for personal development", "D. To decrease smoking rates among young adults" ]
B
38
15638-Interventions-002
pmc.ncbi_PMC2898909
Interventions
What additional component does Intervention-2 include compared to Intervention-1?
[ "A. Consultative feedback", "B. Printed text", "C. A contract to help students select goals", "D. Scripted messages" ]
C
39
15638-Interventions-003
pmc.ncbi_PMC2898909
Interventions
What is the main objective of Intervention-3: Goal Survey + Consult?
[ "A. To address images of successful young adults", "B. To provide image-based feedback tailored to personal development and health behaviors", "C. To avoid alcohol and tobacco use", "D. To influence multiple health habits" ]
B
40
15638-Interventions-004
pmc.ncbi_PMC2898909
Interventions
What is the duration of the interventions described in the study?
[ "A. 2 months", "B. 4 weeks", "C. 1 month", "D. 6 weeks" ]
C
41
15638-Outcomes-001
pmc.ncbi_PMC2898909
Outcomes
What was the p-value for the difference in intention to use alcohol between Int‐1 and Int‐2?
[ "A. p=0.05", "B. p<0.001", "C. p=0.13", "D. p=0.82" ]
B
42
15638-Outcomes-002
pmc.ncbi_PMC2898909
Outcomes
What was the average length of alcohol use score for Int‐2?
[ "A. 2.69±0.2", "B. 2.47±0.2", "C. 2.61±0.2", "D. 3.32±0.3" ]
B
43
15638-Outcomes-003
pmc.ncbi_PMC2898909
Outcomes
What was the p-value for the comparison of the length of alcohol use scores across the three interventions?
[ "A. p=0.05", "B. p<0.001", "C. p=0.13", "D. p=0.82" ]
A
44
15638-Outcomes-004
pmc.ncbi_PMC2898909
Outcomes
What was the average score for 30-day alcohol frequency for Int‐3?
[ "A. 1.91±0.1", "B. 1.74±0.1", "C. 1.81±0.1", "D. 2.69±0.2" ]
C
45
15638-Outcomes-005
pmc.ncbi_PMC2898909
Outcomes
What was the p-value for the 30-day alcohol frequency score comparison?
[ "A. p=0.05", "B. p<0.001", "C. p=0.13", "D. p=0.82" ]
C
46
15638-Outcomes-006
pmc.ncbi_PMC2898909
Outcomes
What was the average quantity of alcohol consumed over 30 days for Int‐1?
[ "A. 3.27±0.3", "B. 3.32±0.3", "C. 3.42±0.3", "D. 2.69±0.2" ]
A
47
15638-Outcomes-007
pmc.ncbi_PMC2898909
Outcomes
What was the p-value for the comparison of 30-day alcohol quantity across interventions?
[ "A. p=0.05", "B. p<0.001", "C. p=0.13", "D. p=0.82" ]
D
48
11397-Methods-001
pmc.ncbi_PMC2639595
Methods
What was the randomisation ratio used in the study?
[ "A. 1:1", "B. 2:1", "C. 3:1", "D. 4:1" ]
B
49
11397-Participants-001
pmc.ncbi_PMC2639595
Participants
How many healthy adults were self-referred to participate in the study?
[ "A. 4000", "B. 5200", "C. 6203", "D. 7200" ]
C
50
11397-Interventions-001
pmc.ncbi_PMC2639595
Interventions
How many types of viruses were included in the TIV vaccine's haemagglutinin antigens?
[ "A. One", "B. Two", "C. Three", "D. Four" ]
C
51
11397-Interventions-002
pmc.ncbi_PMC2639595
Interventions
When did passive surveillance for influenza-like illness (ILI) symptoms begin after vaccination?
[ "A. On the day of vaccination", "B. One week after vaccination", "C. Two weeks after vaccination", "D. One month after vaccination" ]
A
52
11397-Interventions-003
pmc.ncbi_PMC2639595
Interventions
How often did active surveillance contact participants after vaccination?
[ "A. Daily", "B. Weekly", "C. Biweekly", "D. Monthly" ]
C
53
11397-Interventions-004
pmc.ncbi_PMC2639595
Interventions
Was it reported whether the surveillance methods included the entire cohort or just a subset?
[ "A. Yes", "B. No", "C. Only for active surveillance", "D. Only for passive surveillance" ]
B
54
11397-Interventions-005
pmc.ncbi_PMC2639595
Interventions
What was the method of self-reporting ILI symptoms for participants during passive surveillance?
[ "A. Through an online form", "B. Via email", "C. Through a toll-free number", "D. In-person interviews" ]
C
55
11397-Outcomes-001
pmc.ncbi_PMC2639595
Outcomes
What was the blood sample collection timeline for the serological outcomes in this study?
[ "A. Prior to vaccination and 21 days post-vaccination", "B. Only after vaccination", "C. Immediately after vaccination", "D. 7 days before vaccination" ]
A
56
11397-Outcomes-002
pmc.ncbi_PMC2639595
Outcomes
How many reported influenza-like illness (ILI) episodes were there in the study?
[ "A. 370", "B. 814", "C. 46", "D. 240" ]
B
57
11397-Outcomes-003
pmc.ncbi_PMC2639595
Outcomes
What was the total number of ILI events reported among TIV participants?
[ "A. 120", "B. 370", "C. 254", "D. 814" ]
C
58
11397-Outcomes-004
pmc.ncbi_PMC2639595
Outcomes
For the effectiveness outcomes, what was stored at 28 °C before being sent to the National Reference Laboratory?
[ "A. Blood samples", "B. Serum samples", "C. Nasal and throat swabs", "D. Influenza vaccines" ]
C
59
11397-Outcomes-005
pmc.ncbi_PMC2639595
Outcomes
What was the criteria for defining a new ILI episode in this study?
[ "A. At least 5 days free of symptoms", "B. At least 3 days free of symptoms", "C. At least 7 days free of symptoms", "D. At least 10 days free of symptoms" ]
C
60
11397-Outcomes-006
pmc.ncbi_PMC2639595
Outcomes
How many serious adverse events (SAEs) were solicited in the safety data collection?
[ "A. From all participants", "B. From a randomly selected subset of participants", "C. Only from TIV participants", "D. Only from placebo participants" ]
B
61
11397-Outcomes-007
pmc.ncbi_PMC2639595
Outcomes
What scale was used to grade the intensity of reactogenicity symptoms?
[ "A. 0 to 5 grade scale", "B. 0 to 10 grade scale", "C. 0 to 3 grade scale", "D. 1 to 4 grade scale" ]
C
62
11397-Outcomes-008
pmc.ncbi_PMC2639595
Outcomes
What was not considered a primary outcome in this study?
[ "A. Reactogenicity", "B. Safety", "C. Serology", "D. Effectiveness" ]
C
63
09475-Methods-001
spring_s00383-009-2437-4
Methods
How was data collected for this study?
[ "A. Through interviews", "B. Via a self-reported questionnaire", "C. From hospital records", "D. Using online surveys" ]
B
64
09475-Participants-001
spring_s00383-009-2437-4
Participants
What was the minimum age of participants included in the study?
[ "A. 12 years", "B. 16 years", "C. 18 years", "D. 20 years" ]
B
65
09475-Interventions-001
spring_s00383-009-2437-4
Interventions
What type of surgical intervention was compared to pharmacologic treatment in the study?
[ "A. Appendectomy", "B. Laparoscopic surgery", "C. Restorative proctocolectomy with ileoanal anastomosis", "D. Colostomy" ]
C
66
09475-Outcomes-001
spring_s00383-009-2437-4
Outcomes
How was infertility defined in this study?
[ "A. Not using contraceptives", "B. Not becoming pregnant within 6 months", "C. Not becoming pregnant within 12 months", "D. Being unable to conceive after 2 years" ]
C
67
08446-Methods-001
pmc.ncbi_PMC3740324
Methods
What type of study design was used in this RCT?
[ "A. Case-control study", "B. Parallel-group randomized controlled trial", "C. Cohort study", "D. Cross-sectional study" ]
B
68
08446-Methods-002
pmc.ncbi_PMC3740324
Methods
How many total participants were randomized in this study?
[ "A. 50", "B. 99", "C. 100", "D. 149" ]
C
69
08446-Methods-003
pmc.ncbi_PMC3740324
Methods
How many participants were in the loading group?
[ "A. 49", "B. 50", "C. 1", "D. 99" ]
B
70
08446-Methods-004
pmc.ncbi_PMC3740324
Methods
How many participants were analyzed after randomization?
[ "A. 50", "B. 49", "C. 99", "D. 100" ]
C
71
08446-Methods-005
pmc.ncbi_PMC3740324
Methods
What was the unit of analysis in this study?
[ "A. Study center", "B. Study eye per participant", "C. Group of participants", "D. Clinical outcome" ]
B
72
08446-Methods-006
pmc.ncbi_PMC3740324
Methods
Were there any reported losses to follow-up in this study?
[ "A. Yes 1 participant", "B. No none reported", "C. Yes 50 participants", "D. Yes all participants" ]
B
73
08446-Methods-007
pmc.ncbi_PMC3740324
Methods
How was the analysis of participants conducted in this study?
[ "A. As treated", "B. Intention-to-treat", "C. Per-protocol", "D. Convenience sample" ]
B
74
08446-Methods-008
pmc.ncbi_PMC3740324
Methods
What was the reason for the selected sample size in the study?
[ "A. To achieve a high power", "B. Due to a significant expected effect", "C. A reasonable and pragmatic sample size for a monocentric study", "D. Based on previous literature" ]
C
75
08446-Participants-001
pmc.ncbi_PMC3740324
Participants
What percentage of the participants in the study were women?
[ "A. 60%", "B. 73%", "C. 50%", "D. 80%" ]
B
76
08446-Participants-002
pmc.ncbi_PMC3740324
Participants
How many participants were aged between 61 and 70 years?
[ "A. 51", "B. 13", "C. 35", "D. 10" ]
B
77
08446-Participants-003
pmc.ncbi_PMC3740324
Participants
What is the maximum age range of the participants reported in the study?
[ "A. 61-80 years", "B. 71-81 years", "C. ≥ 81 years", "D. 61-70 years" ]
C
78
08446-Participants-004
pmc.ncbi_PMC3740324
Participants
Which condition is NOT included in the exclusion criteria for participants?
[ "A. Active intraocular inflammation", "B. Ocular hypertension (IOP > 25 mmHg)", "C. Treatment-naïve status", "D. Allergy to fluorescein" ]
C
79
08446-Participants-005
pmc.ncbi_PMC3740324
Participants
According to the study, which condition was included in the exclusion criteria?
[ "A. Prescription of ≤ 2 antihypertensive medications", "B. Uncontrolled hypertension", "C. Presence of AMD", "D. Age ≥ 61 years" ]
B
80
08446-Participants-006
pmc.ncbi_PMC3740324
Participants
What aspect of baseline characteristics was reported to be equivalent between groups?
[ "A. Mean age", "B. Mean VAs and mean CMT", "C. Gender distribution", "D. Number of participants" ]
B
81
08446-Interventions-001
pmc.ncbi_PMC3740324
Interventions
What is the dosage of intravitreous bevacizumab used in the study?
[ "A. 0.5 mg", "B. 1.25 mg", "C. 2.5 mg", "D. 5 mg" ]
B
82
08446-Interventions-002
pmc.ncbi_PMC3740324
Interventions
How frequently was the second intervention administered during the initial phase?
[ "A. Every week", "B. Every 2 weeks", "C. Every 4 weeks", "D. Every 6 weeks" ]
C
83
08446-Interventions-003
pmc.ncbi_PMC3740324
Interventions
What is the duration of the follow-up period for the study?
[ "A. 26 weeks", "B. 36 weeks", "C. 54 weeks", "D. 72 weeks" ]
C
84
08446-Interventions-004
pmc.ncbi_PMC3740324
Interventions
How often were assessments for retreatment scheduled?
[ "A. Every 4 weeks", "B. Every 6 weeks", "C. Every 8 weeks", "D. Every 12 weeks" ]
B
85
08446-Outcomes-001
pmc.ncbi_PMC3740324
Outcomes
What is the primary outcome in the RCT study?
[ "A. Proportion with visual improvement defined as gain of ≥ 15 letters from baseline", "B. Proportion with visual stability defined as loss of ≤ 15 letters from baseline", "C. Proportion with systemic adverse events", "D. Proportion with ocular adverse events" ]
B
86
08446-Outcomes-002
pmc.ncbi_PMC3740324
Outcomes
What is one of the secondary outcomes measured in the study?
[ "A. Visual acuity", "B. CMT on OCT", "C. Quality of life", "D. Number of injections" ]
B
87
08446-Outcomes-003
pmc.ncbi_PMC3740324
Outcomes
Which type of adverse events are reported in the study?
[ "A. Neurological and psychiatric adverse events", "B. Ocular and systemic adverse events", "C. Gastrointestinal adverse events", "D. Respiratory and allergic adverse events" ]
B
88
08446-Outcomes-004
pmc.ncbi_PMC3740324
Outcomes
Which outcomes were NOT reported in the study?
[ "A. Proportion with visual stability", "B. CMT on OCT", "C. Number of injections", "D. Occurrence of adverse events" ]
C
89
08446-Outcomes-005
pmc.ncbi_PMC3740324
Outcomes
At what intervals were outcomes assessed during the study?
[ "A. q2 weeks for 54 weeks", "B. q4 weeks for 54 weeks", "C. q6 weeks for 54 weeks", "D. q8 weeks for 54 weeks" ]
C
90
03163-Methods-001
pmc.ncbi_PMC5909820
Methods
What type of study design was used in the trial?
[ "A. Observational study", "B. Cohort study", "C. Randomized controlled trial", "D. Case-control study" ]
C
91
03163-Methods-002
pmc.ncbi_PMC5909820
Methods
How many centers were involved in the trial?
[ "A. One center", "B. Two centers", "C. Three centers", "D. Four centers" ]
B
92
03163-Participants-001
pmc.ncbi_PMC5909820
Participants
What is one of the inclusion criteria for participants in the RCT study?
[ "A. Aged between 60 and 74 years", "B. ≥ 3 documented CDI recurrences", "C. Previous FMT", "D. A history of chronic diarrheal disorder" ]
B
93
03163-Participants-002
pmc.ncbi_PMC5909820
Participants
Which of the following is an exclusion criterion for the RCT study participants?
[ "A. Completed ≥ 10 days of vancomycin therapy", "B. Aged 50 years", "C. History of inflammatory bowel disease", "D. Did not maintain cure after vancomycin therapy" ]
C
94
03163-Participants-003
pmc.ncbi_PMC5909820
Participants
How many days of vancomycin therapy must participants have completed for the most recent CDI prior to the intervention?
[ "A. 5 days", "B. ≥ 10 days", "C. 15 days", "D. 20 days" ]
B
95
03163-Participants-004
pmc.ncbi_PMC5909820
Participants
Which age group is excluded from participating in the RCT study?
[ "A. Aged 25-35 years", "B. Aged 50-60 years", "C. Aged ≥ 75 years", "D. Aged 30-40 years" ]
C
96
03163-Participants-005
pmc.ncbi_PMC5909820
Participants
What must participants not be able to have occurred to be included in the study relating to vancomycin treatment?
[ "A. Have recurrent diarrhea after treatment", "B. Have not completed a course of vancomycin", "C. Have an allergic reaction", "D. Have a diagnosis of colorectal cancer" ]
A
97
03163-Interventions-001
pmc.ncbi_PMC5909820
Interventions
What was the mean weight of the stool used in the fresh donor feces solution infusion?
[ "A. 50 g", "B. 64 g", "C. 70 g", "D. 80 g" ]
B
98
03163-Interventions-002
pmc.ncbi_PMC5909820
Interventions
How many participants received the autologous feces solution infusion?
[ "A. 20", "B. 22", "C. 24", "D. 26" ]
C
99
03163-Interventions-003
pmc.ncbi_PMC5909820
Interventions
What was the volume of the fresh donor feces solution infusion per treatment?
[ "A. 250 mL", "B. 300 mL", "C. 500 mL", "D. 600 mL" ]
C
End of preview.

YAML Metadata Warning:empty or missing yaml metadata in repo card

Check out the documentation for more information.

The dataset is derived exclusively from publicly available sources (e.g., PubMed Central, Cochrane Review) and distributed under the original licenses. We ensure that redistribution complies with the terms of the respective licenses (e.g., CC-BY).

Downloads last month
17